Rationale of responsiveness to checkpoint inhibitor therapy
Activity of checkpoint inhibitor monotherapy for EOC
Author | Study name | Phase | Agent/target | Size | Patient cohort | ORR | PFS |
---|---|---|---|---|---|---|---|
Hamanishi et al. (2015) [7] | (UMIN000005714) | 2 | Nivolumab 1 or 3 mg/kg q2w (PD-1) | n = 20 | Platinum-resistant | 15.0% (95% CI 3.2–37.9) | 3.5 months (95% CI 1.7–3.9) |
Expansion Study (NCT01375842) | 1a | Atezolizumab 0.3–15 mg/kg qw3 (PD-L1) | n = 12 | – | 22.0% (not reported) | 2.9 months (95% CI 1.3–5.5) | |
Varga et al. (2019) [8] | KEYNOTE 028 (NCT02054806) | 1b | Pembrolizumab 10 mg/kg q2w (PD-1) | n = 26 | Progression under previous therapy, PDL1 positive | 11.5% (2.4–30.2) | 1.9 months (95% CI 1.8–3.5) |
Matulonis et al. (2019) [9] | KEYNOTE-100 (NCT02674061) | 2 | Pembrolizumab 200 mg q3w (PD-1) | n = 376 | Platinum sensitive or resistant | 8.0% (95% CI 5.4–11.2) | 2.1 months (95% CI 2.1–2.6) |
Disis et al. (2019) [10] | JAVELIN Solid Tumor NCT01772004 | 1b | Avelumab 10 mg/kg q2w (PD-L1) | n = 125 | Platinum sensitive or resistant | 9.6% (95% CI 5.1–16.2) | 2.6 months (95% CI 1.4–2.8) |
NCT01611558 | 2 | Ipilimumab 10 mg/kg q3w (CTLA-4) | n = 40 | Platinum-sensitive | 10.3% (95% CI 2.9–34.2) | Results pending | |
Konstantinopoulos et al. (2019) [11] | TOPACIO/Keynote-162 NCT02657889 | 1/2 | Niraparib 200 mg daily + pembrolizumab 200 mg q3w (PD-1) | n = 62 | Platinum-resistant | 18.0% (90% CI 11.0–29.0) | 3.4 months (95% CI 2.1–5.1) |
Drew et al. (2019) [12] (Abstract) | MEDIOLA NCT02734004 | 2 | Olaparib 300 mg BID + durvalumab 1500 mg q4w (PD-L1) | n = 32 | BRCA mutated | 71.9% (95% CI 53.3–86.3) | 11.1 months (95% CI 8.2–15.9) |